Copyright
©The Author(s) 2020.
World J Gastroenterol. May 7, 2020; 26(17): 2064-2081
Published online May 7, 2020. doi: 10.3748/wjg.v26.i17.2064
Published online May 7, 2020. doi: 10.3748/wjg.v26.i17.2064
Figure 4 Pathological changes in different groups.
A: Dimethylhydrazine (DMH) + low-dose epigallocatechin gallate (EGCG) group showed moderate to severe dysplasia and local carcinogenesis (Hematoxylin-eosin staining, × 100); B: DMH + low-dose EGCG group showed moderate to severe dysplasia and local carcinogenesis (Hematoxylin-eosin staining, × 400); C: DMH + medium-dose EGCG group showed moderate to severe dysplasia (Hematoxylin-eosin staining, × 100); D: DMH + medium-dose EGCG group showed moderate to severe dysplasia (Hematoxylin-eosin staining, ×400); E: DMH + high-dose EGCG group showed chronic inflammation (Hematoxylin-eosin staining, × 100); F: DMH + high-dose EGCG group showed chronic inflammation (Hematoxylin-eosin staining, × 400); G: DMH group showed signet-ring cell carcinoma (Hematoxylin-eosin staining, × 100); H: DMH group showed signet-ring cell carcinoma (Hematoxylin-eosin staining, × 400).
- Citation: Wang Y, Jin HY, Fang MZ, Wang XF, Chen H, Huang SL, Kong DS, Li M, Zhang X, Sun Y, Wang SM. Epigallocatechin gallate inhibits dimethylhydrazine-induced colorectal cancer in rats. World J Gastroenterol 2020; 26(17): 2064-2081
- URL: https://www.wjgnet.com/1007-9327/full/v26/i17/2064.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i17.2064